How is Major Bleeding in Von Willebrand Disease Treated?
Published: Dec 25, 2023
Von Willebrand Disease (VWD) is a common inherited bleeding disorder. This article reviews treatments available for managing major bleeding episodes in VWD patients.
Contents
Understanding VWD Treatment Strategies
Managing major bleeding in VWD involves increasing von Willebrand factor (VWF) levels in the blood. This can be achieved through VWF concentrates, which are typically administered in situations where bleeding is severe or life-threatening. DDAVP, another treatment, helps release stored VWF, but is less effective for serious bleeding and is usually reserved for minor cases.
The Role of VWF Concentrates
VWF concentrates are the primary treatment for major bleeding in VWD, helping to stabilize clot formation. These are administered intravenously to quickly raise VWF activity levels, essential for those undergoing major surgery or experiencing life-threatening bleeding. Continuous infusion may be necessary if the patient develops inhibitors, which are antibodies that neutralize the infused VWF.
Additional Therapies to Consider
In addition to VWF concentrates, antifibrinolytic agents like tranexamic acid are used to stabilize clots by preventing their breakdown. These are particularly useful for bleeding in areas with high fibrinolytic activity, such as the uterus. Platelet transfusions might also be necessary for patients with low platelet counts, especially in type 2B VWD.
Frequently Asked Questions
VWF concentrates are the primary treatment for serious bleeding episodes in VWD.
DDAVP releases stored VWF but is mostly effective for minor bleeding.
They help stabilize clots by preventing their breakdown.
Prolonged use may lead to elevated factor VIII levels, increasing thrombosis risk.
Key Takeaways
Choosing the right treatment for major bleeding in VWD is crucial and involves careful monitoring and adjustment.
Curious about managing VWD effectively? Talk with Doctronic to explore more options.Related Articles
References
Nichols WL, Hultin MB, James AH, et al. von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia 2008; 14:171.
Laffan MA, Lester W, O'Donnell JS, et al. The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Haematology. Br J Haematol 2014; 167:453.
Always discuss health information with your healthcare provider.